Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Guidance on Selecting Among Recommended Regimens for Rapid Initiation of First-line ART
  • CME

Gregory Huhn, MD
Released: March 25, 2020
Back Next

References

  1. HIV.gov. What is ‘ending the HIV epidemic: a plan for America’? Available at: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Accessed March 16, 2020.
  2. Koenig SP, Dorvil N, Devieux JG, et al. Same-day HIV testing with imitation of antiretroviral therapy versus standard care for person living with HIV: a randomized unblinded trial. PLoS Med. 2017;14:e1002357.
  3. Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: The RapIT randomized controlled trial. PLoS Med. 2016;13:e1002015..
  4. Labhardt ND, Ringera I, Lejone TI, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho. The CASCADE randomized clinical trial. JAMA. 2018;319:1103-1112.
  5. Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. J Acquir Infect Dis Soc. 2017;74:44-51.
  6. Coffey S, Bacchetti P, Sachdev D, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. AIDS. 2019;33:825-832.
  7. Bacon O, Chin JC, Hsu L, et al. The Rapid ART Program Initiative for HIV Diagnoses (RAPID) in San Francisco. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston, Massachusetts. Abstract 93.
  8. Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32:17-23.
  9. Tagarro A, Chan M, Zangari P, et al. Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children. J Acquir Infect Dis Soc. 2018;79:269-276.
  10. Luo L, Wang N, Yue Y, et al. The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study. BMC Infect Dis. 2019;19:257.
  11. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013;208:1202-1211.
  12. Buzon MJ, Martin-Gayo E, Pereyra FJ, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014;88:10056-10065.
  13. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Available at: https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en/. Accessed March 16, 2020.
  14. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA panel. JAMA. 2018;320:379-396.
  15. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: https://aidsinfo.nih.gov/guidelines. Accessed March 16, 2020.
  16. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222-2231.
  17. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063-2072.
  18. Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4:e154-e160.
  19. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073-2082.
  20. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-1818.
  21. McClung RP, Ocfemia CB, Saduvala N, et al. Integrase and other transmitted HIV drug resistance: 23 US jurisdictions, 2013-2016. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, Washington. Abstract 526.
  22. Brown K, Stewart L, Whitcomb JM, et al. Prevalence of darunavir resistance in the United States from 2010 to 2017. AIDS Res Hum Retroviruses. 2018;34:103601043.
  23. Acosta RK, Willkom M, Martin R, et al. Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in hiv-1 treatment-naive patients through 48 weeks. Antimicrob Agents Chemotherapy. 2019;63:e02533-e02518.
  24. Abram ME, Ram RR, Margot NA, et al. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS One. 2017;12:e0172206.
  25. Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study. Clin Infect Dis. 2019;[Epub ahead of print].
  26. LeMessurier J, Traversy G, Varsaneux O, et al. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ. 2018;190:E1350.
  27. Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting. Medicine (Baltimore). 2018;97:e13016.
  28. Halperin J, Conner K, Butler I. A care continuum of immediate ART for newly diagnosed patients and patients presenting later to care at a federally qualified health center in New Orleans. Open Forum Infect Dis. 2019;6:ofz161.
  29. Howard Brown Health. Available at: https://howardbrown.org/about/. Accessed March 16, 2020.
  30. VanderZanden L. The new standard of care: results of a same-day start HIV treatment model. Program and abstracts of the 14th International Conference on HIV Treatment and Prevention Adherence; June 17-19, 2019; Miami, Florida. Abstract 2014.
  31. Cahn P, Madero JS, Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection - 96-week results from the GEMINI studies. Program and abstracts of the 23rd International AIDS Conference; July 21-24, 2019. Abstract WEAB0404LB. 
  32. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143-155.
  33. Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83:310-318.
  34. ClinicalTrials.gov. Rapid test and treat dolutegravir plus lamivudine study in newly diagnosed human immunodeficiency virus (HIV)-1 infected adults. Available at: https://clinicaltrials.gov/ct2/show/NCT03945981. Accessed March 16, 2020.
  35. ClinicalTrials.gov. Prospective pilot study of efficacy, safety and tolerability of bictegravir-based HIV ART same-day treatment evaluations (B-HASTE). Available at: https://clinicaltrials.gov/ct2/show/NCT04249037. Accessed March 16, 2020.
  36. Tittle V, Boffito M, McOwan A, et al. Antiretroviral resistance and management after pre-exposure to prophylaxis. Lancet HIV. 2020;7:e84.
  37. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210:1217-1227.
  38. Zucker J, Carnevale C, Rai AJ, et al. Positive or not, that is the question: HIV testing for individuals on pre-exposure prophylaxis (PrEP). J Acquir Immune Defic Syndr. 2018;78:e11-e13.
  39. ClinicalTrials.gov. A study to evaluate the efficacy and safety of (D/C/F/TAF) once daily fixed dose combination (FDC) regimen in newly diagnosed, antiretroviral treatment-naive human immunodeficiency virus type 1 (HIV-1) infected participants receiving care in a test and treat model of care. Available at: https://clinicaltrials.gov/ct2/show/NCT03227861. Accessed March 16, 2020.
  40. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381:827-840.
  41. Zash R, Holmes L, Makhema J, et al. Surveillance for Neural tube defects following antiretroviral exposure from conception, the Tsepamo study (Botswana). Program and abstracts of the 22nd International AIDS Conference; July 23-27, 2018; Amsterdam, The Netherlands. Abstract TUSY15.
  42. Rogers LM, Cordero AM, Pfeiffer CM, et al. Global folate status in women of reproductive age: a systematic review with emphasis on methodological issues. Ann N Y Acad Sci. 2018;1431:35-57.
  43. Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception - additional surveillance data from Botswana. N Engl J Med. 2019;381:885-887.
  44. Pereira G, Kim A, Jalil E, et al. No occurrences of neural tube defects among 382 women on dolutegravir at pregnancy conception in Brazil. Program and abstracts of the 23rd International AIDS Conference; July 21-24, 2019. Abstract MOAX0104LB.
  45. Dugdale CM, Ciaranello AL, Bekker L, et al. Risks and benefits of dolutegravir- and efavirenz-based strategies for south African women with HIV of childbearing potential: a modeling study. Ann Intern Med. 2019;170 614-625.
  46. Phillips PA, Venter F, Havlir D, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019;6:PE116-E127.
  47. Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-261.
Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?